急性缺血性卒中后双联抗血小板治疗处方分析
这项多中心回顾性队列研究纳入2019年10月1日至2020年6月30日期间1890家医院参与AHA/ASA Get With The Guidelines-Stroke项目的132817例急性缺血性卒中住院患者,评估出院时双联抗血小板治疗(DAPT;阿司匹林加氯吡格雷)的处方模式。结果显示,轻型卒中(NIHSS≤3)患者中47.0%接受DAPT,53.0%未接受;非轻型卒中(NIHSS>3)患者中42.6%接受DAPT。校正患者特征后,医院间DAPT使用存在显著差异(轻型卒中中位OR 2.03,95%CI 1.97-2.09;非轻型卒中中位OR 1.90,95%CI 1.83-1.97),且两类卒中的医院DAPT使用率高度相关(Pearson ρ=0.72;P<.001)。作者认为,提高对循证DAPT指南的依从性可能是缺血性卒中治疗质量改进的目标。
要点
- 轻型缺血性卒中(NIHSS≤3)患者中,47.0%出院时接受DAPT,53.0%(45890例)未接受,与AHA/ASA指南推荐不一致。
- 非轻型卒中(NIHSS>3)患者中,42.6%出院时接受DAPT,而该人群DAPT的风险与获益尚未完全确立。
- 校正患者特征后,医院间DAPT使用差异显著:轻型卒中中位OR 2.03(95%CI 1.97-2.09),非轻型卒中中位OR 1.90(95%CI 1.83-1.97)。
- 医院对轻型卒中更倾向处方DAPT的同时,对非轻型卒中亦更倾向处方DAPT(Pearson ρ=0.72;P<.001)。
- AHA/ASA对轻型缺血性卒中(NIHSS≤3)二级预防给予DAPT(阿司匹林加氯吡格雷)class 1、level of evidence A推荐。
适用人群与场景
- 2019年10月1日至2020年6月30日期间因急性缺血性卒中住院并在出院时接受抗血小板治疗的患者,来自1890家参与AHA/ASA Get With The Guidelines-Stroke项目的医院。
- 轻型缺血性卒中定义为NIHSS评分≤3;非轻型缺血性卒中定义为NIHSS评分>3。
诊断标准与关键阈值
- 轻型缺血性卒中:NIHSS评分≤3。
- 非轻型缺血性卒中:NIHSS评分>3。
处置流程与药物剂量
- AHA/ASA指南推荐轻型缺血性卒中(NIHSS≤3)患者接受双联抗血小板治疗(DAPT;阿司匹林加氯吡格雷)用于二级预防(class 1,level of evidence A)。
研究设计与关键结果
- 多中心回顾性队列研究,纳入132817例患者,来自1890家医院;中位年龄68岁(IQR 59-78),男性68768例(51.8%)。
- 种族分布:亚洲人4282例(3.2%),西班牙裔11254例(8.5%),非西班牙裔黑人27221例(20.5%),非西班牙裔白人84468例(63.6%),其他种族和/或族裔5592例(4.2%)。
- 轻型卒中86551例(65.2%),非轻型卒中46266例(34.8%)。
- 轻型卒中患者中位NIHSS评分1分(IQR 0-2),40661例(47.0%)出院时接受DAPT;非轻型卒中患者中位NIHSS评分6分(IQR 5-9),19703例(42.6%)出院时接受DAPT。
- 轻型卒中患者中45890例(53.0%)未接受DAPT。
- 校正患者特征后,轻型卒中医院层面DAPT处方率中位数44.8%(IQR 33.7%-57.7%),范围0%-91.7%,中位OR 2.03(95%CI 1.97-2.09)。
- 非轻型卒中医院层面DAPT处方率中位数41.4%(IQR 30.0%-53.8%),范围0%-100%,中位OR 1.90(95%CI 1.83-1.97)。
- 医院对轻型卒中更倾向处方DAPT的同时,对非轻型卒中亦更倾向处方DAPT(Pearson ρ=0.72;P<.001)。
证据类型、等级与局限
- 证据类型:多中心回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,提高对循证DAPT实践指南的依从性可能是缺血性卒中治疗质量改进的目标。
- 研究显示超过50%的轻型急性缺血性卒中患者出院时未接受DAPT,而超过40%的非轻型卒中患者接受了DAPT,尽管后者缺乏证据。
指南或共识出处
- AHA/ASA(美国心脏协会/美国卒中协会)指南:对轻型缺血性卒中(NIHSS≤3)二级预防推荐DAPT(阿司匹林加氯吡格雷),class 1,level of evidence A。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: After the publication of the CHANCE (Clopidogrel in High Risk Patients With Acute Nondisabling Cerebrovascular Events) and POINT (Platelet-Oriented Inhibition in New Transient Ischemic Attack and Minor Ischemic Stroke) clinical trials, the American Heart Association/American Stroke Association (AHA/ASA) issued a new class 1, level of evidence A, recommendation for dual antiplatelet therapy (DAPT; aspirin plus clopidogrel) for secondary prevention in patients with minor ischemic stroke (National Institutes of Health Stroke Scale [NIHSS] score ≤3). The extent to which variations in DAPT prescribing patterns remain and the extent to which practice patterns in the US are consistent with evidence-based guidelines are unknown.
OBJECTIVE: To evaluate the discharge DAPT prescribing patterns after publication of the new AHA/ASA guidelines and assess the extent of hospital-level variation in the use of DAPT for secondary prevention in patients with minor stroke (NIHSS score ≤3), as indicated by guidelines, and in patients with nonminor stroke (NIHSS score >3), for whom the risks and benefits of DAPT have not been fully established.
DESIGN, SETTING, AND PARTICIPANTS: This multicenter retrospective cohort study involved 132 817 patients from 1890 hospitals participating in the AHA/ASA Get With The Guidelines-Stroke program. Patients who were hospitalized for acute ischemic stroke and prescribed antiplatelet therapy at discharge between October 1, 2019, and June 30, 2020, were included.
EXPOSURES: Minor ischemic stroke (NIHSS score ≤3) vs nonminor ischemic stroke (NIHSS score >3).
MAIN OUTCOMES AND MEASURES: The primary outcome was DAPT prescription at discharge. The extent to which variations in DAPT use were explained at the hospital level was assessed by calculating the median odds ratio (OR), which was derived using multivariable logistic regression analysis and compared the likelihood that 2 patients with identical clinical features admitted to 2 randomly selected hospitals (1 with higher propensity and 1 with lower propensity for DAPT use) would receive DAPT at discharge. Associations between hospital-level DAPT use among patients with minor vs nonminor stroke were evaluated using Pearson ρ correlation coefficients.
RESULTS: Among 132 817 patients (median [IQR] age, 68 [59-78] years; 68 768 men [51.8%]), 4282 (3.2%) were Asian, 11 254 (8.5%) were Hispanic, 27 221 (20.5%) were non-Hispanic Black, 84 468 (63.6%) were non-Hispanic White, and 5592 (4.2%) were of other races and/or ethnicities (including American Indian or Alaska Native, Native Hawaiian or Pacific Islander, and unable to determine). Overall, 86 551 patients (65.2%) presented with minor ischemic stroke, and 46 266 patients (34.8%) presented with nonminor ischemic stroke. After the 2019 AHA/ASA guideline updates, 40 661 patients (47.0%) with minor stroke (NIHSS median [IQR] score, 1 [0-2]) and 19 703 patients (42.6%) with nonminor stroke (NIHSS median [IQR] score, 6 [5-9]) received DAPT at discharge. Despite guideline recommendations, 45 890 patients (53.0%) with minor stroke did not receive DAPT. After accounting for patient characteristics, substantial hospital-level variations were found in the use of DAPT in those with minor stroke (median [IQR] hospital-level DAPT prescription rate, 44.8% [33.7%-57.7%]; range, 0%-91.7%; median OR, 2.03 [95% CI, 1.97-2.09]) when comparing 2 patients with identical risk factors discharged from 2 randomly selected hospitals, 1 with higher propensity and 1 with lower propensity for DAPT use. The use of DAPT in patients with nonminor stroke also varied significantly (median [IQR] hospital-level DAPT prescription rate, 41.4% [30.0%-53.8%]; range, 0%-100%; median OR, 1.90 [95% CI, 1.83-1.97]). Overall, hospitals that were more likely to prescribe DAPT for minor strokes were also more likely to prescribe DAPT for nonminor strokes (Pearson ρ = 0.72; P < .001).
CONCLUSIONS AND RELEVANCE: This cohort study found that despite updated AHA/ASA guidelines, more than 50% of patients with minor acute ischemic stroke did not receive DAPT at discharge. In contrast, more than 40% of patients with nonminor stroke received DAPT despite lack of evidence in this setting. These findings suggest that enhancing adherence to evidence-based DAPT practice guidelines may be a target for quality improvement in the treatment of patients with ischemic stroke.
参考来源
- Xian Y, Xu H, Matsouaka R, et al. Analysis of Prescriptions for Dual Antiplatelet Therapy After Acute Ischemic Stroke. JAMA Netw Open. 2022. PMID: 35900761. doi:10.1001/jamanetworkopen.2022.24157
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。